We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$107M
1-Year Est. Return
82.62%
This Fund
S&P 500
This Quarter
Est. Return
-2.48%
1 Year Est. Return
+82.62%
3 Year Est. Return
+219.47%
5 Year Est. Return
+202.9%
10 Year Est. Return
–
AUM
$162M
AUM Growth
-$14.7M
(-8.3%)
Cap. Flow
-$3.99M
Cap. Flow
% of AUM
-2.47%
Top 10 Holdings %
Top 10 Hldgs %
35.84%
Holding
111
New
5
Increased
11
Reduced
28
Closed
5
Top Buys
| 1 |
SMED
Sharps Compliance Corp
SMED
|
+$1.1M |
| 2 |
Elutia
ELUT
|
+$604K |
| 3 |
Inuvo
INUV
|
+$535K |
| 4 |
Ooma
OOMA
|
+$430K |
| 5 |
QTEX
QTREX Quantum
QTEX
|
+$338K |
Top Sells
| 1 |
CareDx
CDNA
|
+$3.21M |
| 2 |
CSII
Cardiovascular Systems, Inc.
CSII
|
+$1.05M |
| 3 |
CEMI
Chembio diagnostics, Inc.
CEMI
|
+$796K |
| 4 |
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
|
+$635K |
| 5 |
IIN
IntriCon Corporation
IIN
|
+$633K |
Sector Composition
| 1 | Healthcare | 61.55% |
| 2 | Technology | 15.76% |
| 3 | Communication Services | 6.55% |
| 4 | Industrials | 5.57% |
| 5 | Consumer Staples | 4.81% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
OptimizeRx
OPRX
$125M
| $9.85M | 6.1% |
115,180
-1,250
| -1% | -$78.4K |
|
2
NeoGenomics
NEO
$1.93B
| $7.61M | 4.71% |
157,750
-550
| -0.3% | -$25.5K |
|
3
Natera
NTRA
$38.6B
| $6.95M | 4.31% |
62,400
-50
| -0.1% | -$5.73K |
|
4
Idexx Laboratories
IDXX
$45.4B
| $6.91M | 4.28% |
11,105
| – | – |
|
5
Veracyte
VCYT
$4.73B
| $5.8M | 3.59% |
124,980
| – | – |
|
|
FPAY
6
DELISTED
FlexShopper
FPAY
| $4.57M | 2.83% |
1,478,870
-500
| -0% | -$1.36K |
|
7
Microsoft
MSFT
$2.98T
| $4.37M | 2.7% |
15,493
| – | – |
|
8
Axogen
AXGN
$2.11B
| $4.32M | 2.67% |
273,240
+400
| +0.1% | +$7.18K |
|
|
9
CareDx
CDNA
$2.08B
| $3.83M | 2.37% |
60,442
-42,200
| -41% | -$3.21M |
|
10
Vericel Corp
VCEL
$2.44B
| $3.68M | 2.28% |
75,387
-3,225
| -4% | -$167K |
|
11
Standard BioTools
LAB
$336M
| $3.43M | 2.12% |
520,825
| – | – |
|
|
12
Inuvo
INUV
$18.3M
| $3.38M | 2.09% |
483,353
+68,602
| +17% | +$535K |
|
|
STRM
13
DELISTED
Streamline Health Solutions
STRM
| $3.32M | 2.05% |
126,363
-2,834
| -2% | -$70K |
|
14
Abbott
ABT
$172B
| $3.26M | 2.02% |
27,580
| – | – |
|
15
Eli Lilly
LLY
$1.04T
| $3.17M | 1.96% |
13,708
| – | – |
|
|
CTLP
16
DELISTED
Cantaloupe
CTLP
| $2.95M | 1.83% |
273,725
-4,250
| -2% | -$44K |
|
|
17
Ooma
OOMA
$572M
| $2.83M | 1.75% |
152,075
+22,850
| +18% | +$430K |
|
18
Exagen
XGN
$103M
| $2.81M | 1.74% |
206,230
+5,750
| +3% | +$76.4K |
|
19
LeMaitre Vascular
LMAT
$2.35B
| $2.75M | 1.7% |
51,700
-100
| -0.2% | -$5.63K |
|
20
AtriCure
ATRC
$1.8B
| $2.67M | 1.65% |
38,350
| – | – |
|
21
Digi International
DGII
$2.41B
| $2.65M | 1.64% |
126,300
-500
| -0.4% | -$10.3K |
|
|
CSLT
22
DELISTED
CASTLIGHT HEALTH, INC.
CSLT
| $2.61M | 1.62% |
1,663,000
+30,000
| +2% | +$58.8K |
|
|
VG
23
DELISTED
Vonage Holdings Corporation
VG
| $2.56M | 1.58% |
158,525
| – | – |
|
24
Pfizer
PFE
$143B
| $2.33M | 1.45% |
54,298
+3,450
| +7% | +$153K |
|
25
Castle Biosciences
CSTL
$735M
| $2.2M | 1.36% |
33,150
| – | – |
|
Similar funds
EWL
ECM
HCA
LLI
CWM
SNPAM
ACL
FMI
Perkins Capital Management's Q3 2021 Portfolio in Review
As of Q3 2021, Perkins Capital Management held 111 positions worth $162M, down 8.3% from $176M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Perkins Capital Management's Q3 2021 filing shows 5 new, 11 increased, 28 reduced and 5 closed positions. Its largest new stake was Sharps Compliance Corp: 118,000 shares worth $976K. The largest sale was CareDx, an estimated $3.21M.
By sector, the portfolio is most concentrated in Healthcare at 62% of assets, down from 62% a quarter earlier, followed by Technology and Communication Services.
- Perkins Capital Management's largest Q3 2021 buy was Sharps Compliance Corp: 118,000 shares worth $976K.
- Perkins Capital Management added most to Elutia in Q3 2021, an estimated $604K increase.
- Perkins Capital Management's biggest Q3 2021 reduction was CareDx, cutting an estimated $3.21M.
- Perkins Capital Management fully exited Chembio diagnostics, Inc. in Q3 2021, selling an estimated $796K.
- Perkins Capital Management's ten largest holdings make up 36% of its $162M portfolio in Q3 2021.
- Perkins Capital Management opened 5 new positions and closed 5 in Q3 2021.
- Perkins Capital Management's portfolio value fell 8.3% quarter-over-quarter to $162M.
Based on Perkins Capital Management's 13F filing for Q3 2021, filed 25 Oct 2021.